Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hepion Pharmaceuticals Inc HEPA

Healthcare
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address... see more

Recent & Breaking News (NDAQ:HEPA)

ContraVir Pharmaceuticals Announces Acceptance of Clinical Trial Application in the United Kingdom

GlobeNewswire September 6, 2017

ContraVir Pharmaceuticals Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017

GlobeNewswire September 5, 2017

ContraVir Pharmaceuticals Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program

GlobeNewswire August 21, 2017

ContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017

GlobeNewswire August 8, 2017

ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting® 2017

GlobeNewswire August 3, 2017

Technical Research on Biotech Equities -- Celsion, Sarepta Therapeutics, BioMarin Pharma, and ContraVir Pharma

PR Newswire June 23, 2017

ContraVir Pharmaceuticals to Present at 2017 BIO International Convention

GlobeNewswire June 13, 2017

ContraVir Pharmaceuticals to Present at 2017 Marcum MicroCap Conference

GlobeNewswire June 8, 2017

ContraVir to Advance Second-Generation Formulation of Tenofovir Exalidex (TXL™) for Treatment of Hepatitis B Virus (HBV)

GlobeNewswire May 4, 2017

How These Biotech Stocks are Faring? -- ContraVir Pharma, Intra-Cellular Therapies, Nivalis Therapeutics, and OncoSec Medical

PR Newswire May 2, 2017

ContraVir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants

GlobeNewswire May 1, 2017

Mid-Afternoon Market Update: Dow Gains 250 Points; HealthStream Shares Surge On Earnings Beat

Benzinga.com  April 25, 2017

Mid-Day Market Update: NASDAQ Hits 6,000; Heidrick & Struggles Shares Drop On Downbeat Results

Benzinga.com  April 25, 2017

Mid-Morning Market Update: Markets Open Higher; McDonald's Earnings Beat Estimates

Benzinga.com  April 25, 2017

ContraVir Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants

GlobeNewswire April 25, 2017

ContraVir Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire April 24, 2017

Data Enhances Understanding of ContraVir’s Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL™) and CRV431

GlobeNewswire April 22, 2017

Oral Presentation at EASL Highlights ContraVir’s Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients

GlobeNewswire April 20, 2017

ContraVir to Highlight New Data at EASL The International Liver Congress™ 2017 in Amsterdam, The Netherlands

GlobeNewswire April 11, 2017

ContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg)

GlobeNewswire April 4, 2017